GBT is a biopharmaceutical service provider, mainly engaged in the research and development, production and sales of innovative drugs for the treatment of sickle cell disease in the clinical stage, and provides products such as inlacumab and GBT021601, which can provide effective treatment and prevention services for rare pediatric diseases. Recently, Pfizer announced that it agreed to acquire GBT and plans to acquire the sickle cell disease (SCD) drug maker for a total enterprise value of $5.4 billion.
This article is reprinted from: https://www.itjuzi.com/merger/9192
This site is for inclusion only, and the copyright belongs to the original author.